➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

McKinsey
Colorcon
Johnson and Johnson
Dow
Express Scripts
Harvard Business School

Last Updated: June 13, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR ALOGLIPTIN BENZOATE

« Back to Dashboard

All Clinical Trials for Alogliptin Benzoate

Trial ID Title Status Sponsor Phase Start Date Summary
NCT01990300 Alogliptin/Pioglitazone (Liovel) Liovel Combination Tablets Survey on Long-term Use in Patients With Type 2 Diabetes Mellitus Completed Takeda N/A 2011-11-01 The purpose of this study is to examine the safety and efficacy of long-term use of alogliptin/pioglitazone(Liovel) combination tablets in patients with type 2 diabetes mellitus determined as warranting combination therapy with alogliptin benzoate and pioglitazone hydrochloride
NCT02756832 Local, Multicenter, Observational, Non-Interventional Prospective Study of Alogliptin Benzoate in Participants With Diabetes Mellitus Type 2 Recruiting Takeda Phase 4 2016-09-01 The purpose of this study is to observe clinical response to treatment with alogliptin benzoate (Vipidia) utilization patterns in standard clinical practice.
NCT02856113 Phase 3 Alogliptin Pediatric Study Recruiting Takeda Phase 3 2016-11-01 This study will evaluate the efficacy and safety of alogliptin 25 mg once daily (QD) compared to placebo when administered as monotherapy, or when added onto a background of metformin alone, insulin alone, or a combination of metformin and insulin in pediatric participants 10 to 17 years of age with type 2 diabetes mellitus (T2DM).
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Alogliptin Benzoate

Condition Name

Condition Name for Alogliptin Benzoate
Intervention Trials
Diabetes Mellitus, Type 2 2
Type 2 Diabetes Mellitus 2
Diabetes Mellitus 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Alogliptin Benzoate
Intervention Trials
Diabetes Mellitus, Type 2 6
Diabetes Mellitus 5
Non-alcoholic Fatty Liver Disease 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Alogliptin Benzoate

Trials by Country

Trials by Country for Alogliptin Benzoate
Location Trials
United States 2
Russian Federation 1
Korea, Republic of 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Alogliptin Benzoate
Location Trials
Georgia 1
California 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Alogliptin Benzoate

Clinical Trial Phase

Clinical Trial Phase for Alogliptin Benzoate
Clinical Trial Phase Trials
Phase 4 4
Phase 3 1
N/A 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Alogliptin Benzoate
Clinical Trial Phase Trials
Not yet recruiting 2
Recruiting 2
Completed 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Alogliptin Benzoate

Sponsor Name

Sponsor Name for Alogliptin Benzoate
Sponsor Trials
Takeda 4
Seoul National University Hospital 1
Yonsei University 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Alogliptin Benzoate
Sponsor Trials
Industry 4
Other 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
Baxter
Merck
Boehringer Ingelheim
Harvard Business School
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.